Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...

The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

But before that we’ll cover a talk by Flagship Pioneering CEO Noubar Afeyan and Novartis President Victor Bulto; a panel featuring top voices at Teva, Eli Lilly, and Astellas; an AI deep dive ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab ... Tanezumab and Regeneron/Teva’s fasinumab are the last survivors in a class ...

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...

The global orally disintegrating tablet market size was valued at USD 14.76 billion in 2024 and is projected to grow from USD 16.33 billion in 2025 to USD 28.88 billion by 2033, exhibiting a CAGR of 7 ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.